Oncolytics Biotech® Inc. Announces 2-Arm, Randomized Phase II Pancreatic Cancer Study
Oncolytics Biotech Inc. (“Oncolytics”) announced that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of... - February 04, 2011
Oncolytics Biotech® Inc. Announces Opening of Enrollment in U.S. Phase I Colorectal Cancer Study
The principal investigator of the new colon cancer trial using Reolysin is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York. - January 13, 2011
Press Releases 1 - 2 of 2